ClinicalTrials.gg

Program

13-valent pneumococcal vaccine

Also written as “13-valent pneumococcal conjugate vaccine”, “13-valent Pneumococcal Conjugate Vaccine” and “13vPnC”.

Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Pneumonia · Influenza, Human · HIV Infections, led by 7 companies.

Furthest: phase 4, since Aug 27, 200865 company-led studies, 2 open or runningNext primary completion: Feb 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer570 open or runningphase 4since Aug 27, 2008Sep 19, 2005none ahead
CanSino Biologics31 open or runningphase 3since Apr 8, 2021Sep 18, 2019Feb 15, 2027phase 3 · NCT07017777
Beijing Minhai Biotechnology10 open or runningphase 4since Jan 8, 2024Jan 8, 2024none ahead
Fosun Pharma11 open or runningphase 3since Feb 26, 2023Feb 26, 2023none ahead
Sinovac Biotech10 open or runningphase 1since Oct 13, 2021Oct 13, 2021none ahead
walvax-biotechnology-co-ltd10 open or runningphase 3since Mar 31, 2016Mar 31, 2016none ahead
wuhan-bravovax-co-ltd10 open or runningphase 1since Oct 24, 2022Oct 24, 2022none ahead

Also a collaborator on its studies: Liaoning Chengda Biotechnology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Aug 25, 2006.

  1. May 22, 2018Phase 4 study in VaccinesPfizer · NCT03548337 · 301 enrolled · India
  2. May 25, 2018Phase 2 study in Pneumococcal InfectionsPfizer · NCT03550313 · 565 enrolled · United States
  3. Jun 20, 2018Phase 3 study in Pneumococcal InfectionsPfizer · NCT03571607 · 206 enrolled · Japan
  4. Dec 4, 2018Phase 4 study in VaccinesPfizer · NCT03777865 · 100 enrolled · India
  5. Sep 18, 2019CanSino Biologics’ first study: phase 1 study in Pneumococcal InfectionsNew to CanSino BiologicsCanSino Biologics · NCT04100772 · 237 enrolled · China
  6. Apr 8, 2021Phase 3 study in Pneumococcal InfectionsCanSino Biologics · NCT04841369 · 3,420 enrolled · China
  7. Oct 13, 2021Sinovac Biotech’s first study: phase 1 study in Pneumococcal InfectionsNew to Sinovac BiotechSinovac Biotech · NCT05092386 · 310 enrolled · China
  8. Mar 29, 2022No phase study in Immunogenicity, VaccinePfizer · NCT05372575 · 300 enrolled · China
  9. Apr 7, 2022Phase 4 study in Pneumococcal InfectionsPfizer · NCT05329259 · 200 enrolled · India
  10. Oct 24, 2022wuhan-bravovax-co-ltd’s first study: phase 1 study in Pneumococcal InfectionsNew to wuhan-bravovax-co-ltdwuhan-bravovax-co-ltd · NCT05602480 · 264 enrolled · China
  11. Feb 26, 2023Fosun Pharma’s first study: phase 3 study in Pneumococcal InfectionsNew to Fosun PharmaFosun Pharma · NCT05759520 · 1,800 enrolled · China
  12. Jan 8, 2024Beijing Minhai Biotechnology’s first study: phase 4 study in PneumoniaNew to Beijing Minhai BiotechnologyBeijing Minhai Biotechnology · NCT06210737 · 621 enrolled · China
  13. Jun 4, 2025Phase 3 study in Pneumococcal InfectionsCanSino Biologics · NCT07017777 · 600 enrolled · Thailand
  14. Jun 5, 2025Phase 1 study in Pneumococcal InfectionsPfizer · NCT07019909 · 400 enrolled · China

Ahead

  1. Feb 15, 2027Primary completion: phase 3 study in Pneumococcal InfectionsCanSino Biologics · NCT07017777

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A pneumococcal conjugate vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae, used in children and studied in immunocompromised patients for the prevention of pneumococcal disease”NCIt, by rule

Studies

The newest 60 of 65 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07019909Pneumococcal Infections · China1CompletedPfizerJan 28, 2026400
NCT07017777Pneumococcal Infections · Thailand3Active, not recruitingCanSino BiologicsFeb 15, 2027600
NCT06210737Pneumonia · China4CompletedBeijing Minhai BiotechnologyNov 13, 2022621
NCT05759520Pneumococcal Infections · China3Active, not recruitingFosun PharmaJun 30, 20251,800
NCT05602480Pneumococcal Infections · China1UNKNOWNwuhan-bravovax-co-ltdJun 2024264
NCT05329259Pneumococcal Infections · India4CompletedPfizerNov 30, 2022200
NCT05372575Immunogenicity, Vaccine · China–CompletedPfizerDec 14, 2021300
NCT05092386Pneumococcal Infections · China1CompletedSinovac BiotechMay 26, 2024310
NCT04841369Pneumococcal Infections · China3CompletedCanSino BiologicsMar 30, 20223,420
NCT04100772Pneumococcal Infections · China1CompletedCanSino BiologicsJun 23, 2021237
NCT03777865Vaccines · India4CompletedPfizerApr 17, 2019100
NCT03571607Pneumococcal Infections · Japan3CompletedPfizerNov 16, 2018206
NCT03550313Pneumococcal Infections · United States2TerminatedPfizerNov 5, 2020565
NCT03574389Pneumococcal Infections · China3CompletedPfizerAug 23, 2021936
NCT03548337Vaccines · India4CompletedPfizerDec 20, 2019301
NCT02736240Diseases Caused by Streptococcus Pneumoniae Serotypes3Completedwalvax-biotechnology-co-ltdDec 3, 20172,760
NCT02124161Influenza, Human · United States4CompletedPfizerMay 2015882
NCT02034877Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC · India4CompletedPfizerJul 20151,200
NCT01964716Pneumococcal Vaccines · Gambia3CompletedPfizerSep 2014500
NCT01692886Pneumococcal Infections · China3CompletedPfizerApr 20141,674
NCT01646398Pneumococcal Vaccines · Japan3CompletedPfizerOct 2012764
NCT01531322Pneumococcal Infections · China1CompletedPfizerJan 201272
NCT01392378Pneumococcal Vaccines · Poland4CompletedPfizerJan 2013908
NCT01432262Pneumococcal Infections · Mexico3CompletedPfizerDec 2011324
NCT01200368Healthy Subjects · Japan3CompletedPfizerNov 30, 2011551
NCT01193335Premature Birth · Poland, Spain4CompletedPfizerJan 2014200
NCT0102603813-valent Pneumococcal Vaccine · France3CompletedPfizerNov 2010263
NCT00980655Vaccines, Pneumococcal Conjugate Vaccine · United States, Belgium, Canada and more3CompletedPfizerMay 16, 2013251
NCT00963235HIV Infections · United States3CompletedPfizerMay 2012331
NCT00962780HIV Infections · Romania, South Africa3CompletedPfizerApr 2013303
NCT00918580Pneumococcal Conjugate Vaccine · United States, Egypt, France and more3CompletedPfizerMar 2013158
NCT00853749Invasive Pneumococcal Disease · Iceland3CompletedPfizerDec 16, 200989
NCT00824850Pneumococcal Conjugate Vaccine · United States2CompletedPfizerSep 201075
NCT00824655Pneumococcal Vaccines · Sweden3CompletedPfizerJun 2010234
NCT00761631Healthy Subjects · United States3CompletedPfizerAug 10, 20101,200
NCT00744263Pneumonia, Pneumococcal · Netherlands4CompletedPfizerOct 201384,496
NCT00743652Pneumococcal Infections · United States3CompletedPfizerSep 2010373
NCT00708682Vaccines, Pneumococcal · Mexico3CompletedPfizerMay 2010225
NCT00689351Disease · Korea, Republic of2CompletedPfizerDec 2009180
NCT00688870Vaccines · Taiwan3CompletedPfizerJan 13, 2010168
NCT00676091Vaccines, Pneumococcal Conjugate Vaccine · Brazil3CompletedPfizerSep 2009354
NCT00574795Vaccines, Pneumococcal Conjugate Vaccine · Japan3CompletedPfizerAug 2008193
NCT00574548Pneumococcal Vaccines · United States3CompletedPfizerFeb 2010720
NCT00562354Healthy · Japan3CompletedPfizerDec 2007271
NCT00546572Pneumococcal Infections · United States, Sweden3CompletedPfizerJul 2010938
NCT00521586Influenza, Human · United States3CompletedPfizerDec 20131,116
NCT00508742Pneumococcal Infections · Israel3CompletedPfizerAug 20111,866
NCT00500357Vaccines, Pneumococcal Conjugate Vaccine · South Africa3CompletedPfizerJan 2010105
NCT00500266Pneumococcal Infections · United States, Germany, Sweden3CompletedPfizerApr 20091,053
NCT00492557Pneumococcal Infections3CompletedPfizerFeb 20081,185
NCT00475033Vaccines, Pneumococcal Conjugate Vaccine · Canada3CompletedPfizerMay 2009603
NCT00474539Vaccines, Pneumococcal · Spain3CompletedPfizerMar 2009449
NCT00464945Pneumococcal Vaccines · Poland3CompletedPfizerSep 2008269
NCT00452790Pneumococcal Infections · India3CompletedPfizerOct 2009708
NCT00452452Pneumococcal Infections · Poland3CompletedPfizerMar 2008355
NCT00444457Vaccines, Pneumococcal · United States3CompletedPfizerJun 20091,712
NCT00427895Pneumococcal Infections · United States3CompletedPfizerAug 1, 20112,141
NCT00384059Vaccines, Pneumococcal · United Kingdom3CompletedPfizerOct 2008286
NCT00373958Vaccines, Pneumococcal · United States3CompletedPfizerJun 2008666
NCT00368966Vaccines, Pneumococcal · Spain3CompletedPfizerJul 2008619

How it is read

Names in the registry

  • “13-valent pneumococcal conjugate vaccine”, 23 entries
  • “13-valent Pneumococcal Conjugate Vaccine”, 20 entries
  • “13vPnC”, 9 entries
  • “13-valent pneumococcal conjugate vaccine (13vPnC)”, 8 entries
  • “PCV13”, 5 entries

Codes read as this program: PCV13I.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.